Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Study of 68Ga-DOTA-MGS5 in Advanced Neuroendocrine Tumours
NCT06155994Phase 2Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Jan 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-EVG321 in neuroendocrine tumors (NETs), medullary thyroid carcinoma (MTC), sponsored by Medical University of Innsbruck. Started Jan 2021; status: completed.
02
Drugs
68Ga-EVG321
03
Conditions
neuroendocrine tumors (NETs)medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT06155994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155994.